Navigation Links
Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Date:10/29/2012

CARLSBAD, Calif., Oct. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).  ISIS-FXIRx inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of clots.  In this study, Isis will evaluate the effectiveness of ISIS-FXIRx in reducing the number of thrombotic events in patients after TKA without increasing bleeding.  The combination of robust anti-thrombotic activity with an improved safety profile to currently available anticoagulants could be broadly useful in many therapeutic settings where thrombosis is a serious problem.

"Although there are a number of anti-coagulants on the market today that are considered standard-of-care in multiple therapeutic settings, complications of bleeding associated with these medications remain high and can lead to fatal outcomes," said Harry Buller, Ph.D., M.D., professor of medicine at Academic Medical Center in Netherlands.  "Factor XI is an exciting target because it plays a key role in the formation of clots but inhibiting it does not cause bleeding.  Humans who are deficient in Factor XI tend to have a lower incidence of stroke and venous thrombosis with no evidence of spontaneous bleeding episodes."

The Phase 2 study is a global, multi-center, open-label, comparator-controlled study in up to 400 patients who are undergoing TKA.  The study will compare ISIS-FXIRx safety and activity to enoxaparin, a commonly used anti-coagulant.  In a Phase 1 study in healthy volunteers, ISIS-FXIRx produced robust dose-dependent, statistically significant reduction of greater than 80 percent in Factor XI
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Among High-Risk Infants Versus,Current Standard of Care ... Related Lower Respiratory Infections -, TORONTO, May ... positive results from a large prospective trial,conducted ... The,trial compared motavizumab, the investigational monoclonal antibody,(MAb) ...
... Presentation for Pristiq Occurs at the 55th ... Obstetricians and,Gynecologists, COLLEGEVILLE, Pa., May 09, 2007 ... , presented results from the,first Phase 3 ... moderate-to-severe vasomotor symptoms (hot flashes,and night sweats) ...
Cached Medicine Technology:MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 2Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 4Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 5Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 6
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3
... Blue Plan Experienced a 15 Percent Increase ... a New Report from HealthLeaders-InterStudy, NASHVILLE, ... of managed care market intelligence, reports that ... medication use,through pharmacy programs and public education ...
... Health,Care Systems, Inc. (HCS), a leading provider ... medication reconciliation solutions, has entered,into an agreement with ... not-for-profit hospitals in the nation with 881 licensed,acute ... facility for The,University of Alabama at Birmingham,s Family ...
... treatment could help 3.3 million U.S. sufferers, ... Medical, Inc. today,announced that 98.4 percent of ... called Barrett,s esophagus were free of the ... the HALO ablation,system. The results were published ...
... release of milk in humans, animals , , FRIDAY, July 18 ... speaking? , Researchers have discovered that babies nursing at ... to release of oxytocin, known as the "trust" hormone in ... to be involved in trust and love in both humans ...
... restored brain,s ability to make new cells , , FRIDAY, July ... day may lead to health issues, including depression, a new ... a causal link between abstinence from alcohol drinking and depression," ... and pharmacology in the University of North Carolina School of ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
Cached Medicine News:Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 3Health News:Suckling Infant Triggers 'Trust' Hormone in Moms 2Health News:Research Finds Causal Link Between Ending Drinking, Depression 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading....
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... multimode readers offering 96-channel parallel detection of ... and 1,536-well microtiter plates. Compact workstations ... for the transport of microtiter plates with ... day. The need for mechanical switching required ...
Medicine Products: